Identifying vulnerabilities in treatment resistant lung adenocarcinoma

Abstract

With close to 15,000 new diagnoses in 2022, lung cancer is the 5th most diagnosed form of cancer and the leading cause of cancer-related death in Australia. Whilst clinical advancements in cancer treatment has improved survival outcomes for patients, the heterogeneity of the disease remains a clinical challenge. Particularly, mutations in KRAS are common, and historically, KRAS-mutant lung cancer has been difficult to treat with impaired responses to classical therapeutic strategies, such as chemotherapy and radiotherapy. With approximately 16-17% of all lung cancer cases harbouring mutations in KRAS, understanding the molecular and cellular mechanisms that govern tumourigenesis and progress..